Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFACT-01: Non-prescription Treatments for COVID-19
NCT04621149Phase 2Terminated
- Sponsor
- ProFACT Proteomics
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CloSYS Oral Rinse and famotidine in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by ProFACT Proteomics. Primary endpoint: Reduction in Participant Symptoms of COVID-19 at 3 days. Started Nov 2020; status: terminated.
02
Drugs
CloSYS Oral Rinsefamotidine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04621149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621149.